R03AI103295. Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis. (Colaboración)
- Period:
- from 2013 to 2015
- Financing entity:
- R03AI103295. Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis. (Colaboración)